Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PMS2 negative |
| Therapy | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin |
| Indication/Tumor Type | small intestine adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PMS2 negative | small intestine adenocarcinoma | sensitive | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | Guideline | Actionable | Tecentriq (atezolizumab) in combination with Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) is included in guidelines as adjuvant therapy (category 2A) for patients with small bowel adenocarcinoma with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR, often defined by the loss of PMS2, MLH1, MSH2, or MSH6 expression by IHC) (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |